236 related articles for article (PubMed ID: 17296554)
1. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity.
Ihara M; Yamasaki N; Hagiwara A; Tanigaki A; Kitano A; Hikawa R; Tomimoto H; Noda M; Takanashi M; Mori H; Hattori N; Miyakawa T; Kinoshita M
Neuron; 2007 Feb; 53(4):519-33. PubMed ID: 17296554
[TBL] [Abstract][Full Text] [Related]
2. Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects.
Shehadeh L; Mitsi G; Adi N; Bishopric N; Papapetropoulos S
Mov Disord; 2009 Jan; 24(2):204-10. PubMed ID: 18951507
[TBL] [Abstract][Full Text] [Related]
3. Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.
Ageta-Ishihara N; Yamakado H; Morita T; Hattori S; Takao K; Miyakawa T; Takahashi R; Kinoshita M
Mol Brain; 2013 Aug; 6():35. PubMed ID: 23938054
[TBL] [Abstract][Full Text] [Related]
4. Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies.
Ihara M; Tomimoto H; Kitayama H; Morioka Y; Akiguchi I; Shibasaki H; Noda M; Kinoshita M
J Biol Chem; 2003 Jun; 278(26):24095-102. PubMed ID: 12695511
[TBL] [Abstract][Full Text] [Related]
5. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
7. Climbing the scaffolds of Parkinson's disease pathogenesis.
Spencer B; Crews L; Masliah E
Neuron; 2007 Feb; 53(4):469-70. PubMed ID: 17296545
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.
Chen L; Feany MB
Nat Neurosci; 2005 May; 8(5):657-63. PubMed ID: 15834418
[TBL] [Abstract][Full Text] [Related]
9. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice.
Tanji K; Mori F; Mimura J; Itoh K; Kakita A; Takahashi H; Wakabayashi K
Acta Neuropathol; 2010 Aug; 120(2):145-54. PubMed ID: 20339856
[TBL] [Abstract][Full Text] [Related]
10. Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease.
Tanji K; Mori F; Kito K; Kakita A; Mimura J; Itoh K; Takahashi H; Kamitani T; Wakabayashi K
J Neuropathol Exp Neurol; 2011 Oct; 70(10):879-89. PubMed ID: 21937912
[TBL] [Abstract][Full Text] [Related]
11. The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
Sitz JH; Baumgärtel K; Hämmerle B; Papadopoulos C; Hekerman P; Tejedor FJ; Becker W; Lutz B
Neuroscience; 2008 Dec; 157(3):596-605. PubMed ID: 18938227
[TBL] [Abstract][Full Text] [Related]
12. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
13. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates.
Arawaka S; Sato H; Sasaki A; Koyama S; Kato T
Acta Neuropathol Commun; 2017 Jun; 5(1):48. PubMed ID: 28619113
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A
PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
18. Extracellular α-synuclein enters dopaminergic cells by modulating flotillin-1-assisted dopamine transporter endocytosis.
Kobayashi J; Hasegawa T; Sugeno N; Yoshida S; Akiyama T; Fujimori K; Hatakeyama H; Miki Y; Tomiyama A; Kawata Y; Fukuda M; Kawahata I; Yamakuni T; Ezura M; Kikuchi A; Baba T; Takeda A; Kanzaki M; Wakabayashi K; Okano H; Aoki M
FASEB J; 2019 Sep; 33(9):10240-10256. PubMed ID: 31211923
[TBL] [Abstract][Full Text] [Related]
19. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
20. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.
Unger EL; Eve DJ; Perez XA; Reichenbach DK; Xu Y; Lee MK; Andrews AM
Neurobiol Dis; 2006 Feb; 21(2):431-43. PubMed ID: 16230020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
